SR One’s Simeon George on how China is rewriting biotech’s venture playbook

AI Summary

Investor Simeon George of SR One highlights how China's advancing biotech sector is reshaping venture investment strategies by increasing competition and focusing funding on more viable projects. This shift impacts the global biotech ecosystem and investment trends.

The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”